Literature DB >> 7996478

Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes.

P J Emmerson1, M R Liu, J H Woods, F Medzihradsky.   

Abstract

The binding parameters of radiolabeled DAMGO (mu), DPDPE and pCl-DPDPE (delta) and 5 alpha, 7 alpha, 8 beta-N-methyl-N-[7-(1- pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl]benzeneacetamide (also known as U69593, kappa) and the affinity and selectivity profiles of various opioid agonists and antagonists at the three opioid receptor types were determined in membranes from brain cortex of rhesus monkey. Among the 10 opioids with established mu-selective actions, etonitazene inhibited the binding of [3H]DAMGO with a Ki of 0.02 nM (0.01 nM without sodium) and exhibited mu/delta and mu/kappa selectivities of 8800 and 11,650, respectively. DAMGO had a Ki of 1.23 nM and was about 500-fold more selective at mu receptors compared with delta and kappa sites. Other mu opioids with higher than 100-fold binding selectivity were fentanil and sufentanil. Highly selective delta opioids were DPDPE, deltorphin II and naltrindole. With the exception of N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH, all investigated putative delta opioids bound to delta sites with low Kis, i.e., 0.04 nM, 0.13 nM and 1.4 nM for naltrindole, (+/-)-4-[(alpha-R*)-alpha-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl) -3- hydroxybenzyl]-N,N-diethylbenzamide and DPDPE, respectively. In this series, the displacement of [3H]pCl-DPDPE yielded results similar to those obtained with [3H]DPDPE. With nanomolar Kis of 0.70, 0.89, 0.25 and 0.06, respectively, the highest kappa selectivity was displayed by (trans)-(+/-)-3,4-dichloro-N-methyl- N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide and U69593, followed by dynorphin 1-13 and norbinaltorphimine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7996478

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  57 in total

1.  In vivo pharmacological resultant analysis reveals noncompetitive interactions between opioid antagonists in the rat tail-withdrawal assay.

Authors:  E A Walker
Journal:  Br J Pharmacol       Date:  2006-10-30       Impact factor: 8.739

Review 2.  Targeted opioid receptor antagonists in the treatment of alcohol use disorders.

Authors:  Mark J Niciu; Albert J Arias
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

3.  Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.

Authors:  Pablo Barrio; Lluisa Ortega; Josep Guardia; Carlos Roncero; Lara Yuguero; Antoni Gual
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

4.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

Review 5.  [Nalmefene: a novel pharmacotherapeutic option for alcoholism].

Authors:  M Soyka
Journal:  Nervenarzt       Date:  2014-05       Impact factor: 1.214

Review 6.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

7.  Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms.

Authors:  Angela N Henderson-Redmond; Tammy E Lowe; Xi B Tian; Daniel J Morgan
Journal:  Brain Res Bull       Date:  2017-08-02       Impact factor: 4.077

8.  The effects of morphine, naloxone, and κ opioid manipulation on endocrine functioning and social behavior in monogamous titi monkeys (Callicebus cupreus).

Authors:  B J Ragen; N Maninger; S P Mendoza; K L Bales
Journal:  Neuroscience       Date:  2014-12-06       Impact factor: 3.590

9.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

Review 10.  Potential uses of naltrexone in emergency department patients with opioid use disorder.

Authors:  Evan Stuart Bradley; David Liss; Stephanie Pepper Carreiro; David Eric Brush; Kavita Babu
Journal:  Clin Toxicol (Phila)       Date:  2019-03-04       Impact factor: 4.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.